Precision Epigenomics Inc was selected to present their findings regarding the development of a liquid biopsy assay for non-small cell lung to the leadership and faculty of the University of Arizona.
Recent Posts
- Precision Epigenomics Announces Unprecedented Early-Stage Sensitivity Data for EPISEEK® Multi-Cancer Early Detection Test
- Industry Excitement: GenomeWeb Survey Confirms High Interest in MCED Tests
- Precision Epigenomics and Front Line Mobile Health to Deliver EPISEEK Cancer Testing to First Responders in TX, CO, & GA
- New Clinical Test Developed to Accurately Classify Pleural Effusions
- Precision Epigenomics: Tactical Steps in Multi-Cancer Early Detection and Beyond
Recent Comments
No comments to show.
